Phase II trial of bisantrene in non-small cell lung cancer

Thomas P. Miller; Frederick R. Ahmann; Cindy Mackel; Bernard R. Greenberg; David S. Alberts

doi:10.1007/BF00170764

Phase II trial of bisantrene in non-small cell lung cancer

Thomas P. Miller
, Frederick R. Ahmann
, Cindy Mackel
, Bernard R. Greenberg
, David S. Alberts

Research output: Contribution to journal › Article › peer-review

Abstract

Eighteen evaluable patients with non-small cell lung cancer (NSCLC) were treated with bisantrene at a dose of 200 mg/m² once a week for 3 consecutive weeks. Courses of treatment were repeated every 4 weeks. This dose schedule caused leukopenia (< 3,500 cells/ μl) in all patients. There were no objective responses in 18 patients. Bisantrene in this myelosuppressive dose schedule did not have significant activity in patients with NSCLC.

Original language	English (US)
Pages (from-to)	393-395
Number of pages	3
Journal	Investigational New Drugs
Volume	3
Issue number	4
DOIs	https://doi.org/10.1007/BF00170764
State	Published - Dec 1985

Keywords

bisantrene
non-small cell lung cancer

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00170764

Cite this

@article{44f4f0432cf74444a60eb60850547a52,

title = "Phase II trial of bisantrene in non-small cell lung cancer",

abstract = "Eighteen evaluable patients with non-small cell lung cancer (NSCLC) were treated with bisantrene at a dose of 200 mg/m2 once a week for 3 consecutive weeks. Courses of treatment were repeated every 4 weeks. This dose schedule caused leukopenia (< 3,500 cells/ μl) in all patients. There were no objective responses in 18 patients. Bisantrene in this myelosuppressive dose schedule did not have significant activity in patients with NSCLC.",

keywords = "bisantrene, non-small cell lung cancer",

author = "Miller, \{Thomas P.\} and Ahmann, \{Frederick R.\} and Cindy Mackel and Greenberg, \{Bernard R.\} and Alberts, \{David S.\}",

year = "1985",

month = dec,

doi = "10.1007/BF00170764",

language = "English (US)",

volume = "3",

pages = "393--395",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - Phase II trial of bisantrene in non-small cell lung cancer

AU - Miller, Thomas P.

AU - Ahmann, Frederick R.

AU - Mackel, Cindy

AU - Greenberg, Bernard R.

AU - Alberts, David S.

PY - 1985/12

Y1 - 1985/12

N2 - Eighteen evaluable patients with non-small cell lung cancer (NSCLC) were treated with bisantrene at a dose of 200 mg/m2 once a week for 3 consecutive weeks. Courses of treatment were repeated every 4 weeks. This dose schedule caused leukopenia (< 3,500 cells/ μl) in all patients. There were no objective responses in 18 patients. Bisantrene in this myelosuppressive dose schedule did not have significant activity in patients with NSCLC.

AB - Eighteen evaluable patients with non-small cell lung cancer (NSCLC) were treated with bisantrene at a dose of 200 mg/m2 once a week for 3 consecutive weeks. Courses of treatment were repeated every 4 weeks. This dose schedule caused leukopenia (< 3,500 cells/ μl) in all patients. There were no objective responses in 18 patients. Bisantrene in this myelosuppressive dose schedule did not have significant activity in patients with NSCLC.

KW - bisantrene

KW - non-small cell lung cancer

UR - https://www.scopus.com/pages/publications/0022356752

UR - https://www.scopus.com/pages/publications/0022356752#tab=citedBy

U2 - 10.1007/BF00170764

DO - 10.1007/BF00170764

M3 - Article

C2 - 4086247

AN - SCOPUS:0022356752

SN - 0167-6997

VL - 3

SP - 393

EP - 395

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

Phase II trial of bisantrene in non-small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this